Better pricing and operating execution can produce attractive profits in a growing individual market. Q2 revenue reached $4.88 billion and the medical loss ratio improved to 79.2%, following a difficult prior-year period. These results are encouraging but cannot be annualized without considering seasonality, risk adjustment and policy changes. The investment is fundamentally an underwriting and regulatory case.

What the Market May Be Mispricing

Debate	Research judgment
Ultimate medical costs and pricing adequacy	Better pricing and operating execution can produce attractive profits in a growing individual market.
ACA subsidies, regulation and risk adjustment	Medical loss ratio, administrative ratio, risk-adjustment accuracy, member retention and pricing adequacy determine unit economics.
Full-year profitability and statutory capital	Q2 adjusted EBITDA was about $415 million, but insurer cash inflows include premiums and settlement timing that are not freely distributable.

Oscar provides individual and family health insurance, primarily through the Affordable Care Act marketplace, with technology and member-service capabilities supporting plan operations. Premium revenue funds medical claims, administration and required insurance capital. Membership growth depends on pricing, distribution, subsidies, network design and regulatory rules. Risk-adjustment receivables and liabilities materially affect comparisons and cash timing.

Business Takeaway

Oscar provides individual and family health insurance, primarily through the Affordable Care Act marketplace, with technology and member-service capabilities supporting plan operations. Medical loss ratio, administrative ratio, risk-adjustment accuracy, member retention and pricing adequacy determine unit economics.

The individual market can benefit from labor-market flexibility and employer coverage changes. Subsidy policy, eligibility enforcement and insurer participation can change the market abruptly. Total insured lives should not be treated as a stable TAM independent of policy and affordability.

Market-Share Analysis

Comparable same-definition share data for the subject and its principal rivals were not established. TAM estimates and company-specific volume measures are not treated as directly comparable market shares. The positioning analysis below is more reliable than a table of unmatched percentages.

Competitive Scale / Position

Company / Platform	Primary Position	Relative Scale	Growth Direction	Investment Relevance
Centene — Ambetter (CNC)	Direct: ACA individual-market plans in overlapping counties	Product scope; no matched operating-scale series	Competes where plans are offered together	Customer choice in the stated segment only
Molina (MOH)	Direct segment: exchange coverage where offered	Product scope; no matched operating-scale series	Verify plan-year and county availability	Customer choice in the stated segment only
Local Blue Cross Blue Shield plans	Direct: individual-market coverage in overlapping counties	Product scope; no matched operating-scale series	County-level premiums and networks determine competition	Customer choice in the stated segment only

Industry Takeaway

Total insured lives should not be treated as a stable TAM independent of policy and affordability. The base case requires evidence of profitable adoption within that market.

Competitive Landscape

The same member must be able to choose the competing ACA plan in the same county and plan year. National managed-care scale does not establish directly comparable exchange economics.

Competitor	Market Share	Positioning	Advantages vs. Company	Disadvantages vs. Company	Current Direction
Centene — Ambetter (CNC)	No consistent comparable series	Direct: ACA individual-market plans in overlapping counties	Exchange-plan distribution and networks	Consolidated Medicaid economics are not an ACA plan proxy	Competes where plans are offered together
Molina (MOH)	No consistent comparable series	Direct segment: exchange coverage where offered	Managed-care operations and provider relationships	Medicaid-heavy group mix differs from Oscar	Verify plan-year and county availability
Local Blue Cross Blue Shield plans	No consistent comparable series	Direct: individual-market coverage in overlapping counties	Local provider networks and brand recognition	Separate regional insurers have different pricing and scale	County-level premiums and networks determine competition

Moat Assessment

Technology, service and distribution offer differentiation, but do not create an impregnable underwriting moat. Network access, pricing and regulatory execution remain central. Larger insurers have substantial scale and negotiating power.

Moat direction: Stable — an analytical judgment about product and distribution economics, not a measured market-share claim.

Competitive Takeaway

Technology, service and distribution offer differentiation, but do not create an impregnable underwriting moat. The direct rivals determine commercial pressure; diversified or sector anchors provide valuation context and are not substitutes for direct competition.

Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2026. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

Period	Revenue	Growth	Gross Margin	Operating Margin	FCF	FCF Margin	SBC	Diluted Shares	Cash	Debt
FY2024	9,178	56.54%	N/A	0.62%	950.3	10.36%	109.82	266	1,527	373.75
FY2025	11,701	27.50%	N/A	-3.39%	1,058	9.05%	87.65	262	2,774	498.8
Q1 FY2026	$5.718	N/D	N/D	12313.5%	$2,610.186 (derived: CFO - capex)	45648.6%	$15.969	329.751	$4,805.139	N/D
Q2 FY2026	$6.095	N/D	N/D	6376.3%	$2,080.583 (derived: current YTD - prior YTD)	34135.9%	$20.654 (derived: current YTD - prior YTD)	333.432	$4,075.612	N/D
H1 FY2026	$11.813	N/D	N/D	9250.1%	$4,690.769 (derived: CFO - capex)	39708.5%	$36.623	331.292	$4,075.612	N/D
Q3 FY2026	$6.295	N/D	N/D	2827.9%	−$1,211.896 (derived: current YTD - prior YTD)	-19251.7%	$22.291 (derived: current YTD - prior YTD)	346.457	$4,466.858	N/D
9M FY2026	$18.108	N/D	N/D	7017.6%	$3,478.873 (derived: CFO - capex)	19211.8%	$58.914	339.281	$4,466.858	N/D

Financial Takeaways

Q2 adjusted EBITDA was about $415 million, but insurer cash inflows include premiums and settlement timing that are not freely distributable. Regulatory capital and claims reserves must be preserved. The model uses sustainable EPS rather than capitalizing standardized FCF or treating all insurance cash as surplus.

Premium float, risk-adjustment settlements and claims timing inflate or reverse reported operating cash. CFO-minus-capex is not distributable insurer cash. Statutory capital, medical losses and sustainable earnings constrain valuation.

Financial direction: Mixed — assess the reported trend alongside dilution and the balance sheet.

Current Valuation

Metric	Value
Price Snapshot	$32.41 — 2026-11-03 regular-session close, America/New_York
Market Capitalization	$10.38B
Enterprise Value	N/A — not used; see capital/settlement accounting discussion
Trailing P/E	17.64
Provider forward P/E	18.47
P/B	5.06

Comparable Company Analysis

Company	Relevance	Public / Private	Forward P/E	P/B	Growth / Margin / Risk Context
OSCR — Oscar Health, Inc.	Subject company	Public	18.47	5.06	individual health insurance; 3Y revenue-growth estimate 27.77%; operating margin 4.11%
CNC — Centene	Direct Ambetter exchange segment; Medicaid-heavy group multiple	Public	15.21	1.55	managed care and exchange insurance; 3Y revenue-growth estimate 4.30%; operating margin 1.86%
MOH — Molina	Direct only where exchange plans overlap; different group mix	Public	31.22	2.74	government and exchange health insurance; 3Y revenue-growth estimate 5.52%; operating margin 0.70%
Local Blue Cross Blue Shield plans	Direct: individual-market coverage in overlapping counties	Operating alternative / no standalone security	N/D — no matched snapshot collected	N/D — no matched snapshot collected	County-level premiums and networks determine competition

Comparable takeaway: The same member must be able to choose the competing ACA plan in the same county and plan year. National managed-care scale does not establish directly comparable exchange economics. Quoted multiples retain their original dated snapshot; missing matched multiples are not estimated. Consolidated parent multiples do not isolate the competing product. No mechanical peer average is used.

The base terminal P/E is 16×, versus the provider's current forward P/E of 18.47×. Holding that quoted multiple constant on this model's 2029 EPS gives an illustrative present value of $29.58, versus the central base FV of $25.63. Earnings definitions differ, so this is a sensitivity check; it makes the dependence on a rerating or derating explicit.

Valuation Scenarios

Scenario	Key Assumptions	Fair Value	Probability	Probability Rationale	Return From Price Snapshot
Bear	3Y revenue CAGR -2%; sustainable 2029 EPS $0.60 after compensation; 10× P/E; 16% discount rate; Policy or claims deterioration constrains 2029 EPS to $0.60.	$3.84	35%	Execution, financing or competitive setbacks remain credible	-88.2%
Base	3Y revenue CAGR 12%; sustainable 2029 EPS $2.50 after compensation; 16× P/E; 16% discount rate; Adequate pricing and operational discipline produce $2.50 of 2029 EPS.	$25.63	45%	Most likely operating trajectory, requiring measurable progress	-20.9%
Bull	3Y revenue CAGR 22%; sustainable 2029 EPS $4.50 after compensation; 20× P/E; 16% discount rate; A durable individual-market expansion produces $4.50 of 2029 EPS.	$57.66	20%	Successful product conversion and operating leverage; not assured	+77.9%
Probability-Weighted	Sum of each scenario value × its probability	$24.41	100%	Judgmental scenario probabilities	-24.7%

Valuation Takeaway

• Primary valuation method: Present value of sustainable 2029 equity earnings × scenario P/E, plus assumed interim dividends. The three-year discount horizon approximates late-2029 earning power.
• Cross-check methods: Direct competition, quoted peer multiples, current cash conversion, and the separate revenue/share/net-margin bridge in the valuation workpaper.
• Key valuation dependencies: Ultimate medical costs and pricing adequacy; ACA subsidies, regulation and risk adjustment; Full-year profitability and statutory capital. All forward figures are independent research assumptions, not company guidance or consensus.
• Valuation confidence / Risk Level: 35/100 / High. Scenario values are sensitive to sustainable earnings and terminal multiples.
• Margin-of-safety conclusion: Avoid at $33.66. New-file boundaries use Strong Buy = min(P/W FV ÷ 1.5, 1.1 × bear FV), Buy upper = P/W FV ÷ 1.25, Avoid above = P/W FV ÷ 0.90. Returns are to present fair value, not annualized returns or price targets for a particular date.

Mark Bertolini brings industry experience and has improved operating focus. Guidance credibility should be assessed across full underwriting years, especially after sharp changes in claims experience. Monitor reserve development, risk-adjustment estimates and growth-related capital requirements.

Management Takeaway

Monitor reserve development, risk-adjustment estimates and growth-related capital requirements.

Analyzed call: Q2 2026, complete material Q&A · Research snapshot: 2026-10-21

The table consolidates related questions and follow-ups from each material participant in the complete call.

Analyst / Firm	Core Question	Management Response	Research Read-Through
Andrew Mok / Barclays	Are utilization trends across medical categories within expectations?	Management said overall trends are within expectations.	Confirm that this opportunity converts into profitable recurring demand.
Jessica Tassan / Piper Sandler	What explains the revised medical loss ratio and its reconciliation?	Management said a prior-year adjustment explains much of the improvement.	Confirm that this opportunity converts into profitable recurring demand.
Parker Snure / Raymond James	How does the tax-credit transition affect 2027 pricing?	Management said the transition has largely been absorbed.	Treat the stated timetable as conditional on demonstrated execution.
Stephen Baxter / Wells Fargo	What explains sequential differences in claims?	Management said metal-tier mix affects the comparison.	Confirm that this opportunity converts into profitable recurring demand.
Scott Fidel / Goldman Sachs	How do scale and risk-adjustment transfers affect administration and results?	Management described scale benefits and the expected transfer mechanics.	Confirm that this opportunity converts into profitable recurring demand.
Raj Kumar / Stephens Inc.	How can the employer marketplace improve affordability?	Management said its tools can improve affordability for employers.	Confirm that this opportunity converts into profitable recurring demand.
Jonathan Yong / UBS	How do competition and enrollment-integrity actions affect 2027 and near-term churn?	Management said integrity actions increase near-term churn.	Treat the stated timetable as conditional on demonstrated execution.
Michael Ha / Baird	Has the underlying full-year risk-adjustment expectation changed?	Management said the full-year expectation is unchanged.	Confirm that this opportunity converts into profitable recurring demand.
Dave Windley / Jefferies	How much further distribution and plan-mix optimization is possible?	Management said further optimization is possible but smaller than the prior transition.	Confirm that this opportunity converts into profitable recurring demand.
Kevin Fischbeck / Bank of America	What drives the increase in guidance?	Management said prior-period development accounts for much of the uplift.	Treat the stated timetable as conditional on demonstrated execution.
Justin Lake / Wolfe Research	When will enrollment-integrity disenrollments affect membership?	Management said disenrollment timing shifted into the second half.	Confirm that this opportunity converts into profitable recurring demand.

Analyst-Q&A Takeaway

Much of the guidance improvement reflects favorable prior-period development. Underlying claims, risk adjustment and integrity-driven disenrollment should determine sustainable earnings rather than the headline profit increase.

Source	Type	Date / Period	What It Supports
Oscar Health Announces Record Financial Results for First Half 2026 and Raises Full Year 2026 Outlook :: Oscar Health, Inc. (OSCR)	Company IR / earnings filing	Q2 2026	Latest operating results, guidance, products and financial supplement
OSCR complete earnings-call transcript	Transcript	Q2 2026	Prepared remarks and all material Q&A exchanges
OSCR regular-session historical price	Market data	2026-10-20 close	Common price used in returns, scores and zones
OSCR valuation statistics	Market data	2026-10-20 close; ratios retrieved 2026-10-21	Market capitalization, shares, quoted multiples and current ratios
OSCR historical income statement	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical income statement; source-native currency and definitions
OSCR historical balance sheet	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical balance sheet; source-native currency and definitions
OSCR historical cash flows	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical cash flows; source-native currency and definitions
Centene statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
Molina statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
2025 10-K — plan markets and competition	Regulatory filing / primary product evidence	FY2025; checked 2026-10-28	Individual-market competition and network/geographic differences
SEC XBRL company facts — OSCR	Regulatory filing (as tagged)	FY2026, through 2026-09-30	Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics

Research context

• Company: Oscar Health, Inc.

• Ticker: OSCR

• Exchange: NYSE

• Sector / Industry: Financials / individual health insurance

• Template version: 2.7

• Research date: 2026-10-21

• Valuation / score price snapshot: $32.41 — 2026-11-03 regular-session close, America/New_York

• Tracking tier: Primary Watchlist

• Owned: No

• Primary operating period reviewed: Q2 2026

• Historical period reviewed: TTM, FY 2025, FY 2024; latest balance-sheet date shown below

• Latest investor presentation reviewed: Results release and associated financial tables; no separate slide deck materially used

• Latest earnings call reviewed: Q2 2026, complete material Q&A

• Latest post-earnings management commentary reviewed: No separate later management presentation incorporated

• Price snapshot date: 2026-11-03

• Price snapshot time / timezone: Regular-session close, America/New_York (including exchange half-days)

• Competitor / analyst-Q&A audit: 2026-10-28; original operating, price and valuation snapshots retained.

OSCR — Oscar Health, Inc.

Company & Research Metadata

• Company: Oscar Health, Inc.

• Ticker: OSCR

• Exchange: NYSE

• Sector / Industry: Financials / individual health insurance

• Template version: 2.7

• Research date: 2026-10-21

• Valuation / score price snapshot: $32.41 — 2026-11-03 regular-session close, America/New_York

• Tracking tier: Primary Watchlist

• Owned: No

• Primary operating period reviewed: Q2 2026

• Historical period reviewed: TTM, FY 2025, FY 2024; latest balance-sheet date shown below

• Latest investor presentation reviewed: Results release and associated financial tables; no separate slide deck materially used

• Latest earnings call reviewed: Q2 2026, complete material Q&A

• Latest post-earnings management commentary reviewed: No separate later management presentation incorporated

• Price snapshot date: 2026-11-03

• Price snapshot time / timezone: Regular-session close, America/New_York (including exchange half-days)

• Competitor / analyst-Q&A audit: 2026-10-28; original operating, price and valuation snapshots retained.

What's Changed Since Previous Review

Current Review: 2026-10-28

Previous Review: 2026-10-21

Update Trigger: Competitor relevance and analyst-Q&A correction

Area	Previous View	Current View	Investment Impact
Competition	Preceding operating and comparable-company classifications	Product/customer/geographic boundaries corrected; direct rivals separated from substitutes, partners and valuation anchors	Corrects the competitive comparison; does not by itself re-underwrite the valuation
Analyst questions	Prior source-linked Q&A summaries	Complete questions and sentence-form management answers; all 11 existing rows retained	Improves readability while preserving the recorded exchange meaning
Valuation and scores	Approved operating/price snapshots, scenarios, scores and decisions	Preserved	No price refresh, rerank or change to valuation assumptions in this correction pass

Thesis: No new fundamental thesis determination is made in this correction pass. The prior investment decision is preserved; the corrected competitive scope should govern the next substantive review.

Investment Snapshot

Metric	Current View
Price Snapshot	$32.41 — 2026-11-03 regular-session close, America/New_York
Rating / Zone Status	Avoid
Bear / Base / Bull Fair Value	$3.84 / $25.63 / $57.66
Scenario Probabilities	35% / 45% / 20%
Probability-Weighted Fair Value	$24.41
Probability-Weighted Expected Return	-24.7%
Bear-Case Return	-88.2%
Strong Buy Zone	≤ $4.22
Buy Zone	>$4.22–$19.53
Avoid Chasing Above	> $27.12
Quality Score / Tier	61.6 / Tier C
Opportunity Score / Rank	23.9 / #73 of 76
Risk Level	High
Tracking / Ownership	Primary Watchlist / Not Owned

Decision rationale: OSCR is Avoid at $33.66, with -27.5% probability-weighted upside and -88.6% bear-case return. Better pricing and operating execution can produce attractive profits in a growing individual market. Confidence is 35/100 because the earnings conversion, competitive and capital assumptions below remain conditional.

Investment Thesis

Better pricing and operating execution can produce attractive profits in a growing individual market. Q2 revenue reached $4.88 billion and the medical loss ratio improved to 79.2%, following a difficult prior-year period. These results are encouraging but cannot be annualized without considering seasonality, risk adjustment and policy changes. The investment is fundamentally an underwriting and regulatory case.

What the Market May Be Mispricing

Debate	Research judgment
Ultimate medical costs and pricing adequacy	Better pricing and operating execution can produce attractive profits in a growing individual market.
ACA subsidies, regulation and risk adjustment	Medical loss ratio, administrative ratio, risk-adjustment accuracy, member retention and pricing adequacy determine unit economics.
Full-year profitability and statutory capital	Q2 adjusted EBITDA was about $415 million, but insurer cash inflows include premiums and settlement timing that are not freely distributable.

Business Overview

Oscar provides individual and family health insurance, primarily through the Affordable Care Act marketplace, with technology and member-service capabilities supporting plan operations. Premium revenue funds medical claims, administration and required insurance capital. Membership growth depends on pricing, distribution, subsidies, network design and regulatory rules. Risk-adjustment receivables and liabilities materially affect comparisons and cash timing.

Business Takeaway

Oscar provides individual and family health insurance, primarily through the Affordable Care Act marketplace, with technology and member-service capabilities supporting plan operations. Medical loss ratio, administrative ratio, risk-adjustment accuracy, member retention and pricing adequacy determine unit economics.

Industry, TAM & Market Share

The individual market can benefit from labor-market flexibility and employer coverage changes. Subsidy policy, eligibility enforcement and insurer participation can change the market abruptly. Total insured lives should not be treated as a stable TAM independent of policy and affordability.

Market-Share Analysis

Comparable same-definition share data for the subject and its principal rivals were not established. TAM estimates and company-specific volume measures are not treated as directly comparable market shares. The positioning analysis below is more reliable than a table of unmatched percentages.

Competitive Scale / Position

Company / Platform	Primary Position	Relative Scale	Growth Direction	Investment Relevance
Centene — Ambetter (CNC)	Direct: ACA individual-market plans in overlapping counties	Product scope; no matched operating-scale series	Competes where plans are offered together	Customer choice in the stated segment only
Molina (MOH)	Direct segment: exchange coverage where offered	Product scope; no matched operating-scale series	Verify plan-year and county availability	Customer choice in the stated segment only
Local Blue Cross Blue Shield plans	Direct: individual-market coverage in overlapping counties	Product scope; no matched operating-scale series	County-level premiums and networks determine competition	Customer choice in the stated segment only

Industry Takeaway

Total insured lives should not be treated as a stable TAM independent of policy and affordability. The base case requires evidence of profitable adoption within that market.

Customer Economics

Medical loss ratio, administrative ratio, risk-adjustment accuracy, member retention and pricing adequacy determine unit economics. Growth is valuable only when premiums cover ultimate medical costs and required capital. A favorable first half can be offset by later claims development or adverse risk adjustment.

Customer-Economics Takeaway

The economic test is Full-year profitability and statutory capital. A favorable first half can be offset by later claims development or adverse risk adjustment.

Competitive Landscape & Moat

Competitive Landscape

The same member must be able to choose the competing ACA plan in the same county and plan year. National managed-care scale does not establish directly comparable exchange economics.

Competitor	Market Share	Positioning	Advantages vs. Company	Disadvantages vs. Company	Current Direction
Centene — Ambetter (CNC)	No consistent comparable series	Direct: ACA individual-market plans in overlapping counties	Exchange-plan distribution and networks	Consolidated Medicaid economics are not an ACA plan proxy	Competes where plans are offered together
Molina (MOH)	No consistent comparable series	Direct segment: exchange coverage where offered	Managed-care operations and provider relationships	Medicaid-heavy group mix differs from Oscar	Verify plan-year and county availability
Local Blue Cross Blue Shield plans	No consistent comparable series	Direct: individual-market coverage in overlapping counties	Local provider networks and brand recognition	Separate regional insurers have different pricing and scale	County-level premiums and networks determine competition

Moat Assessment

Technology, service and distribution offer differentiation, but do not create an impregnable underwriting moat. Network access, pricing and regulatory execution remain central. Larger insurers have substantial scale and negotiating power.

Moat direction: Stable — an analytical judgment about product and distribution economics, not a measured market-share claim.

Competitive Takeaway

Technology, service and distribution offer differentiation, but do not create an impregnable underwriting moat. The direct rivals determine commercial pressure; diversified or sector anchors provide valuation context and are not substitutes for direct competition.

Financial Profile

Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2026. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

Period	Revenue	Growth	Gross Margin	Operating Margin	FCF	FCF Margin	SBC	Diluted Shares	Cash	Debt
FY2024	9,178	56.54%	N/A	0.62%	950.3	10.36%	109.82	266	1,527	373.75
FY2025	11,701	27.50%	N/A	-3.39%	1,058	9.05%	87.65	262	2,774	498.8
Q1 FY2026	$5.718	N/D	N/D	12313.5%	$2,610.186 (derived: CFO - capex)	45648.6%	$15.969	329.751	$4,805.139	N/D
Q2 FY2026	$6.095	N/D	N/D	6376.3%	$2,080.583 (derived: current YTD - prior YTD)	34135.9%	$20.654 (derived: current YTD - prior YTD)	333.432	$4,075.612	N/D
H1 FY2026	$11.813	N/D	N/D	9250.1%	$4,690.769 (derived: CFO - capex)	39708.5%	$36.623	331.292	$4,075.612	N/D
Q3 FY2026	$6.295	N/D	N/D	2827.9%	−$1,211.896 (derived: current YTD - prior YTD)	-19251.7%	$22.291 (derived: current YTD - prior YTD)	346.457	$4,466.858	N/D
9M FY2026	$18.108	N/D	N/D	7017.6%	$3,478.873 (derived: CFO - capex)	19211.8%	$58.914	339.281	$4,466.858	N/D

Financial Takeaways

Q2 adjusted EBITDA was about $415 million, but insurer cash inflows include premiums and settlement timing that are not freely distributable. Regulatory capital and claims reserves must be preserved. The model uses sustainable EPS rather than capitalizing standardized FCF or treating all insurance cash as surplus.

Premium float, risk-adjustment settlements and claims timing inflate or reverse reported operating cash. CFO-minus-capex is not distributable insurer cash. Statutory capital, medical losses and sustainable earnings constrain valuation.

Financial direction: Mixed — assess the reported trend alongside dilution and the balance sheet.

Management & Capital Allocation

Mark Bertolini brings industry experience and has improved operating focus. Guidance credibility should be assessed across full underwriting years, especially after sharp changes in claims experience. Monitor reserve development, risk-adjustment estimates and growth-related capital requirements.

Management Takeaway

Monitor reserve development, risk-adjustment estimates and growth-related capital requirements.

Valuation

Current Valuation

Metric	Value
Price Snapshot	$32.41 — 2026-11-03 regular-session close, America/New_York
Market Capitalization	$10.38B
Enterprise Value	N/A — not used; see capital/settlement accounting discussion
Trailing P/E	17.64
Provider forward P/E	18.47
P/B	5.06

Comparable Company Analysis

Company	Relevance	Public / Private	Forward P/E	P/B	Growth / Margin / Risk Context
OSCR — Oscar Health, Inc.	Subject company	Public	18.47	5.06	individual health insurance; 3Y revenue-growth estimate 27.77%; operating margin 4.11%
CNC — Centene	Direct Ambetter exchange segment; Medicaid-heavy group multiple	Public	15.21	1.55	managed care and exchange insurance; 3Y revenue-growth estimate 4.30%; operating margin 1.86%
MOH — Molina	Direct only where exchange plans overlap; different group mix	Public	31.22	2.74	government and exchange health insurance; 3Y revenue-growth estimate 5.52%; operating margin 0.70%
Local Blue Cross Blue Shield plans	Direct: individual-market coverage in overlapping counties	Operating alternative / no standalone security	N/D — no matched snapshot collected	N/D — no matched snapshot collected	County-level premiums and networks determine competition

Comparable takeaway: The same member must be able to choose the competing ACA plan in the same county and plan year. National managed-care scale does not establish directly comparable exchange economics. Quoted multiples retain their original dated snapshot; missing matched multiples are not estimated. Consolidated parent multiples do not isolate the competing product. No mechanical peer average is used.

The base terminal P/E is 16×, versus the provider's current forward P/E of 18.47×. Holding that quoted multiple constant on this model's 2029 EPS gives an illustrative present value of $29.58, versus the central base FV of $25.63. Earnings definitions differ, so this is a sensitivity check; it makes the dependence on a rerating or derating explicit.

Valuation Scenarios

Scenario	Key Assumptions	Fair Value	Probability	Probability Rationale	Return From Price Snapshot
Bear	3Y revenue CAGR -2%; sustainable 2029 EPS $0.60 after compensation; 10× P/E; 16% discount rate; Policy or claims deterioration constrains 2029 EPS to $0.60.	$3.84	35%	Execution, financing or competitive setbacks remain credible	-88.2%
Base	3Y revenue CAGR 12%; sustainable 2029 EPS $2.50 after compensation; 16× P/E; 16% discount rate; Adequate pricing and operational discipline produce $2.50 of 2029 EPS.	$25.63	45%	Most likely operating trajectory, requiring measurable progress	-20.9%
Bull	3Y revenue CAGR 22%; sustainable 2029 EPS $4.50 after compensation; 20× P/E; 16% discount rate; A durable individual-market expansion produces $4.50 of 2029 EPS.	$57.66	20%	Successful product conversion and operating leverage; not assured	+77.9%
Probability-Weighted	Sum of each scenario value × its probability	$24.41	100%	Judgmental scenario probabilities	-24.7%

Valuation Takeaway

• Primary valuation method: Present value of sustainable 2029 equity earnings × scenario P/E, plus assumed interim dividends. The three-year discount horizon approximates late-2029 earning power.
• Cross-check methods: Direct competition, quoted peer multiples, current cash conversion, and the separate revenue/share/net-margin bridge in the valuation workpaper.
• Key valuation dependencies: Ultimate medical costs and pricing adequacy; ACA subsidies, regulation and risk adjustment; Full-year profitability and statutory capital. All forward figures are independent research assumptions, not company guidance or consensus.
• Valuation confidence / Risk Level: 35/100 / High. Scenario values are sensitive to sustainable earnings and terminal multiples.
• Margin-of-safety conclusion: Avoid at $33.66. New-file boundaries use Strong Buy = min(P/W FV ÷ 1.5, 1.1 × bear FV), Buy upper = P/W FV ÷ 1.25, Avoid above = P/W FV ÷ 0.90. Returns are to present fair value, not annualized returns or price targets for a particular date.

Analyst Questions

The table consolidates related questions and follow-ups from each material participant in the complete call.

Analyst / Firm	Core Question	Management Response	Research Read-Through
Andrew Mok / Barclays	Are utilization trends across medical categories within expectations?	Management said overall trends are within expectations.	Confirm that this opportunity converts into profitable recurring demand.
Jessica Tassan / Piper Sandler	What explains the revised medical loss ratio and its reconciliation?	Management said a prior-year adjustment explains much of the improvement.	Confirm that this opportunity converts into profitable recurring demand.
Parker Snure / Raymond James	How does the tax-credit transition affect 2027 pricing?	Management said the transition has largely been absorbed.	Treat the stated timetable as conditional on demonstrated execution.
Stephen Baxter / Wells Fargo	What explains sequential differences in claims?	Management said metal-tier mix affects the comparison.	Confirm that this opportunity converts into profitable recurring demand.
Scott Fidel / Goldman Sachs	How do scale and risk-adjustment transfers affect administration and results?	Management described scale benefits and the expected transfer mechanics.	Confirm that this opportunity converts into profitable recurring demand.
Raj Kumar / Stephens Inc.	How can the employer marketplace improve affordability?	Management said its tools can improve affordability for employers.	Confirm that this opportunity converts into profitable recurring demand.
Jonathan Yong / UBS	How do competition and enrollment-integrity actions affect 2027 and near-term churn?	Management said integrity actions increase near-term churn.	Treat the stated timetable as conditional on demonstrated execution.
Michael Ha / Baird	Has the underlying full-year risk-adjustment expectation changed?	Management said the full-year expectation is unchanged.	Confirm that this opportunity converts into profitable recurring demand.
Dave Windley / Jefferies	How much further distribution and plan-mix optimization is possible?	Management said further optimization is possible but smaller than the prior transition.	Confirm that this opportunity converts into profitable recurring demand.
Kevin Fischbeck / Bank of America	What drives the increase in guidance?	Management said prior-period development accounts for much of the uplift.	Treat the stated timetable as conditional on demonstrated execution.
Justin Lake / Wolfe Research	When will enrollment-integrity disenrollments affect membership?	Management said disenrollment timing shifted into the second half.	Confirm that this opportunity converts into profitable recurring demand.

Analyst-Q&A Takeaway

Much of the guidance improvement reflects favorable prior-period development. Underlying claims, risk adjustment and integrity-driven disenrollment should determine sustainable earnings rather than the headline profit increase.

Thesis Monitoring

Driver	Current State	Positive Trigger / Catalyst	Negative Trigger / Falsifier	What It Changes
Ultimate medical costs and pricing adequacy	Better pricing and operating execution can produce attractive profits in a growing individual market.	Revenue trajectory sustains approximately 12% annual growth on a comparable basis	Growth remains below the -2% bear assumption over a full operating cycle	Revenue outlook and scenario probabilities
ACA subsidies, regulation and risk adjustment	Medical loss ratio, administrative ratio, risk-adjustment accuracy, member retention and pricing adequacy determine unit economics.	After-cost earnings progress toward the base implied net margin of 3.8%	Competition, credit losses or service costs make that margin trajectory unattainable	Margins, moat score and valuation multiple
Full-year profitability and statutory capital	Q2 adjusted EBITDA was about $415 million, but insurer cash inflows include premiums and settlement timing that are not freely distributable.	Financing and compensation remain consistent with 325.3M economic shares in the 2029 base case	Required capital or cumulative dilution materially exceeds the model without matching earnings	Financial score, confidence and downside value

Quality & Opportunity Scorecards

Quality Score

Component	Score	Weight	Weighted Contribution	Evidence
Business durability and economics	60	25%	15.0	Medical loss ratio, administrative ratio, risk-adjustment accuracy, member retention and pricing adequacy determine unit economics.
Moat and competitive position	48	25%	12.0	Technology, service and distribution offer differentiation, but do not create an impregnable underwriting moat.
Growth runway and durability	80	20%	16.0	The individual market can benefit from labor-market flexibility and employer coverage changes.
Financial quality and balance sheet	62	15%	9.3	Q2 adjusted EBITDA was about $415 million, but insurer cash inflows include premiums and settlement timing that are not freely distributable.
Management, governance and capital allocation	62	15%	9.3	Mark Bertolini brings industry experience and has improved operating focus.
Quality Score	61.6	100%	61.6	Weighted score, independent of ownership and current price

• Quality Tier: C
• Speculative override: None

Opportunity Score

Component	Raw Input	Normalized Score	Weight	Weighted Contribution
Quality	61.6	61.6	30%	18.5
Probability-weighted upside	-24.7%	0.6	35%	0.2
Bear-case downside	-88.2%	0.0	20%	0.0
Risk / valuation confidence	35	35.0	15%	5.3
Opportunity Score		23.9	100%	23.9

• Opportunity Rank: #73 of 76
• Zone Status: Avoid

Portfolio Context

• Tracking tier: Primary Watchlist
• Owned: No
• Tracking source of truth: my_watchlist.md
• Portfolio source of truth: portfolio/holdings.md
• Scoring independence: Ownership, account, shares, position size and cost basis do not change research, valuation, Quality, Opportunity, rank or zones.

Investment Decision History

Timestamp	Price	Rating	Zone Status	Buy Zone	Strong Buy Zone	Avoid Chasing Above	Base FV	P/W FV	P/W Return	Quality	Opportunity / Rank	Change / Rationale
2026-10-21 (America/New_York)	$33.66	Avoid	Avoid	>$4.22–$19.53	≤ $4.22	> $27.12	$25.63	$24.41	-27.5%	61.6	23.7 / #67	Initial missing-file analysis; common-universe ranking; independent scenario assumptions

---

Material Sources

Source	Type	Date / Period	What It Supports
Oscar Health Announces Record Financial Results for First Half 2026 and Raises Full Year 2026 Outlook :: Oscar Health, Inc. (OSCR)	Company IR / earnings filing	Q2 2026	Latest operating results, guidance, products and financial supplement
OSCR complete earnings-call transcript	Transcript	Q2 2026	Prepared remarks and all material Q&A exchanges
OSCR regular-session historical price	Market data	2026-10-20 close	Common price used in returns, scores and zones
OSCR valuation statistics	Market data	2026-10-20 close; ratios retrieved 2026-10-21	Market capitalization, shares, quoted multiples and current ratios
OSCR historical income statement	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical income statement; source-native currency and definitions
OSCR historical balance sheet	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical balance sheet; source-native currency and definitions
OSCR historical cash flows	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical cash flows; source-native currency and definitions
Centene statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
Molina statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
2025 10-K — plan markets and competition	Regulatory filing / primary product evidence	FY2025; checked 2026-10-28	Individual-market competition and network/geographic differences
SEC XBRL company facts — OSCR	Regulatory filing (as tagged)	FY2026, through 2026-09-30	Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics